home / stock / atha / atha quote
Last: | $2.57 |
---|---|
Change Percent: | 0.0% |
Open: | $2.52 |
Close: | $2.57 |
High: | $2.65 |
Low: | $2.48 |
Volume: | 74,169 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.57 | $2.52 | $2.57 | $2.65 | $2.48 | 74,169 | 07-04-2024 |
$2.57 | $2.52 | $2.57 | $2.65 | $2.48 | 74,169 | 07-03-2024 |
$2.52 | $2.51 | $2.52 | $2.5399 | $2.46 | 62,591 | 07-02-2024 |
$2.51 | $2.61 | $2.51 | $2.64 | $2.49 | 45,594 | 07-01-2024 |
$2.65 | $2.66 | $2.65 | $2.69 | $2.56 | 120,897 | 06-28-2024 |
$2.64 | $2.43 | $2.64 | $2.65 | $2.43 | 144,711 | 06-27-2024 |
$2.41 | $2.31 | $2.41 | $2.42 | $2.2515 | 89,270 | 06-26-2024 |
$2.19 | $2.36 | $2.19 | $2.37 | $2.13 | 154,605 | 06-25-2024 |
$2.37 | $2.37 | $2.37 | $2.431 | $2.32 | 61,648 | 06-24-2024 |
$2.34 | $2.27 | $2.34 | $2.36 | $2.18 | 121,272 | 06-21-2024 |
$2.29 | $2.58 | $2.29 | $2.58 | $2.28 | 91,871 | 06-20-2024 |
$2.6 | $2.59 | $2.6 | $2.65 | $2.52 | 147,544 | 06-19-2024 |
$2.6 | $2.59 | $2.6 | $2.65 | $2.52 | 147,544 | 06-18-2024 |
$2.6 | $2.53 | $2.6 | $2.61 | $2.48 | 95,981 | 06-17-2024 |
$2.54 | $2.52 | $2.54 | $2.56 | $2.47 | 145,877 | 06-14-2024 |
$2.55 | $2.59 | $2.55 | $2.61 | $2.53 | 94,138 | 06-13-2024 |
$2.6 | $2.61 | $2.6 | $2.64 | $2.53 | 135,513 | 06-12-2024 |
$2.55 | $2.53 | $2.55 | $2.61 | $2.475 | 70,213 | 06-11-2024 |
$2.55 | $2.52 | $2.55 | $2.59 | $2.47 | 171,136 | 06-10-2024 |
$2.55 | $2.51 | $2.55 | $2.5846 | $2.44 | 198,177 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western Distri...